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ABSTRACT 
Introduction 
Post transplant malignancy (PTM) is a recognized long term complication in renal transplant 
recipients. Many studies have been conducted on this group of patients over the last 50 
years to assess the impact of various immunosuppressant drug regimens, geographical 
locations, ethnicity, and age at the time of transplant on the risk of developing a PTM. The 
incidence of PTM has been shown from these studies to vary from 3% to 11%. Many 
inconsistencies exist in these studies, but the one common finding is that the incidence of 
malignancy is increased in renal transplant recipients compared to the general population. 
Aims and Objectives 
The objectives of this study were to determine the incidence of PTM at Charlotte Maxeke 
Johannesburg Academic Hospital (CMJAH) in the period from 1990 to 2010; to calculate the 
mean time to diagnosis of PTM; determine the association of PTM and immunosuppressive 
drug regimens and identify risk factors associated with developing a malignancy post renal 
transplant. 
 Methods 
The study design was a retrospective review of the medical records of patients transplanted 
between 01/01/1990 and 31/12/2010 at CMJAH, South Africa. All recipients above 18years 
of age transplanted during this study period were included in the review. All recipients who 
rejected, died or were transferred to other centres within six months of transplantation were 
excluded. A total of 668 records were included in this study for analysis. Information 
retrieved from the files included patient demographics (age at transplantation; gender; ethnic 
group, year of transplantation), aetiology of end-stage renal disease, the source of graft, the 
number of times treated for rejection, oncogenic viruses diagnosed, immunosuppressant 
regimens and outcomes of the recipients. For those recipients who developed a malignancy, 
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the time from transplantation to diagnosis of cancer was calculated and the histological 
diagnoses documented. 
Results 
The incidence of PTM in this study was 7.0% (95% CI 5.2-9.4) for the era under review. The 
cumulative incidence of cancer from transplantation increased with follow-up time. The mean 
time to diagnosis of malignancy was: 3.4 years, 6.6 years, 7.4 years and 8.1 years for 
Kaposi Sarcoma (KS), post transplant lymphoproliferative disorder (PTLD), skin and solid 
organ malignancy, respectively. The distribution of post transplant malignancy (PTM) was 
skin cancers 44.7%; KS 23.4%; PTLD 14.9%; solid organ tumours 17.0 %. The recipients 
who developed cancer were significantly older at transplantation with a mean age of 42.9 
years compared to those without PTM whose mean age was 36.3 years. Age and year of 
transplantation period 1996-2000 were independent risk factors for developing a malignancy 
in this cohort. 
Discussion 
There was no change in the incidence of PTM at CMJAH, occurring in 7% of the transplant 
recipients in the period of review (1990-2010) compared to 7.0% reported for the period 
1966-1989, despite the change in the demographic patterns of the patients, 
immunosuppressive regimens and improved surveillance for cancers. No individual 
immunosuppressant drug appears to pose a risk for cancer significantly, instead, the 
prolonged general state of immune suppression in this group of patients seems to be the 
main risk factor of note. Recipients transplanted at an older age and those with long post 
renal transplantation follow-up should be closely monitored and routine surveillance for 
cancers done.  
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CHAPTER 1 - INTRODUCTION 
1.1  BACKGROUND 
 Kidney transplantation is the preferred treatment modality of renal replacement therapy 
(RRT) to date ineligible recipients for the management of end-stage renal disease (ESRD)  
[1, 2].Transplantation has been shown to reverse many of the complications of chronic 
kidney disease (CKD) and thus has led to improvement in the quality and length of life in 
these patients [2, 3].  
Currently, the sources of kidney grafts are related living donors (RLD), unrelated living 
donors (URLD) and cadaveric donors. These donors have Human Leukocyte Antigen (HLA) 
serotypes that are often different from that of the recipient to varying degrees and hence the 
need for individualised   immunosuppression protocols to prevent rejection of the graft by the 
recipient. Usually, two to three different classes of immunosuppressants with different 
mechanisms of action are used for induction and maintenance in the recipient. The rational 
use of immunosuppressants and good clinical practice ensures normal functioning of the 
graft and its prolonged survival. In 1996, a renal allograft was estimated to have a half-life of 
approximately 21.6 years when received from a living donor and 13.8 years when obtained 
from a cadaveric donor in the United States [4]. 
The leading causes of death with a functional renal graft are cardiovascular diseases, 
infections and post transplant malignancy (PTM), respectively [2, 5].Numerous studies 
postulate that with improved patient care, the leading cause of death with a functioning renal 
graft in the 21st century will be PTM [6]. 
In a retrospective study, Howard et al. showed that PTM was a rapidly rising cause of 
mortality in the renal transplant population in the USA. These results are summarised in 
Table 1.1 below. This rise in mortality from PTM is likely due to longer patient survival post-
transplant, older age at transplant recipients, and the newer immunosuppressive drugs in 
use [7]. 
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Table 1.1 – Causes of Death Post Kidney Transplant during 1970-1999 by Transplant Era 
Cause of death Transplant Era    
 1970-1979 1980-1989 1990-1999 
Infection (%) 42 42 28 
Cardiac (%) 9.6 23.8 30.2 
Neurologic (%) 2.4 5.2 8.5 
Cancer (%) 1.2 5.2 13.2 
Reproduced with permission from publisher [7] 
Findings from retrospective and prospective studies in various countries of diverse 
geography and population groups have been inconsistent with regards to the incidence of 
PTM and the impact of the various risk factors on the incidence thereof [8]. This indicates the 
need to evaluate PTM in each transplant centre, at different time periods and to make 
comparisons with other centres [9].  
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1.2  LITERATURE REVIEW 
1.2.1  Definition of Post-Transplant Malignancy  
Post transplant malignancy refers to a malignancy that develops in an organ transplant 
recipient [10, 11]. The time from transplantation to diagnosis varies depending on 
malignancy type  and the risk factors at play in each recipient [10]. The malignancy may 
arise as a result of the transmission of the recipient of  undiagnosed cancer in the donor, 
recurrent   cancer in the recipient or it may  develop de novo  [5, 12].The risk of de novo 
PTM is 0.2% while that of donor-derived PTM is 1.3 % [7]. 
1.2.2  Epidemiology of PTM in Kidney Transplant 
The risk of developing malignancy has been shown to be increased in the post transplant 
population has been shown to be   3-5 times that of non- transplant population [12]. The risk 
is higher for skin cancers, lymphomas, Kaposi sarcoma (KS) and epithelial cancers[10]. The 
incidence of PTM varies in different parts of the world due to the impact of various risk 
factors on   a recipient. These include environmental and population-related risk factors (the 
latter including racial and genetic factors) the type of cancers endemic in the region ( e.g. 
gastrointestinal in Asia ), and the local availability of screening tests for cancer [12]. The 
incidence ranges from 1.6 -11% with an average of about 6% [13-15]. Given the varied 
incidence of PTM across transplant centres, the epidemiology is best discussed 
geographical regions and reference made to the cancer registries for renal transplant 
patients in the different regions [9, 16]. 
Africa 
In South Africa (SA), the incidence of PTM ranges from 3.4% to 8.1% in studies conducted 
in Johannesburg, Durban and Cape Town [17-20]. These studies were performed at   
different immunosuppressants and political eras in SA, between 1966 and 2009. In all these 
studies, skin cancer was most prevalent among the Caucasian recipients, accounting for 
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over 80% of PTM in this population group. On the other hand, KS was most common among 
the black recipients and was not observed in the Caucasian population[19]. 
CMJAH is one of 6 centers in SA offering renal transplantation to patients in the public health 
sector. Moosa et al. from Stellenbosch   reviewed a cohort of patients transplanted between 
1976 and 1999 and found Kaposi sarcoma (KS) to be the most prevalent PTM while 
Margolius et al found skin cancers to be the commonest PTM in Johannesburg before 1989 
[18, 21, 22]. Maharaj and Assounga in Durban found PTLD  to be the commonest PTM 
between 1982 and 2009 [20]. 
In Egypt, the incidence of PTM in a cohort followed up for 18 years was 2.3% and after 30 
years of follow-up, the incidence increased to 3.97% [14, 23].Kaposi Sarcoma was the 
commonest cancer, accounting for over 50% of the malignancies. In the study by Bakr et al., 
bladder cancer constituted 14% of the PTM and was related to schistosomiasis which is 
endemic in this area [14]. 
Middle East  
The Middle East Society for Organ Transplantation (MESOT) Transplant Registry has noted 
the incidence of PTM to be  1.8 -2.2% with KS and skin cancers, especially squamous cell 
carcinoma (SCC), being most common [11, 15]. A multicentre study conducted in Iran 
showed the incidence of PTM to be 2.17%, with skin cancer contributed over 50%  of the 
post transplant cancers [8]. In this study, more males than females were affected, and older 
patients were at higher risk. 
Asia  
Studies conducted in  Asian countries have shown the incidence of PTM to range from 3.5% 
to 11% and the cumulative incidence of cancer to increase with increasing the time from 
date of transplantation [24]. Renal and gastrointestinal malignancies are more common in 
China, Taiwan, and Tokyo compared to other regions of the world [25].Post-transplant 
5 
 
lymphoproliferative disease (PTLD) is the most prevalent cancer among Indian renal 
transplant recipients. In a cohort from northern India followed up for 30 years,72.5% of the 
cases of PTM were PTLD [26].  
ANZDATA (Australia and New Zealand Dialysis and Transplant Registry) 
Australia and New Zealand with a climate which is predominantly sunny and  a population 
mainly composed of the Caucasian race, have a  6.3-12% incidence of PTM [27]. Skin 
cancer is the most common PTM with an incidence as high as 24% [15]. Kaposi Sarcoma is 
also very common in the renal recipients with 40-fold risk compared to the normal population 
[28]. 
The United States of America 
A review of the Cincinnati Transplant Tumor Registry (CTTR) has shown the most frequent 
PTM to be PTLD and squamous cell carcinoma of the lip, skin, cervix and vulva, and  KS 
[12].  
Europe  
 The  European Dialysis and Transplantation Association and European Renal Association 
(EDTA-ERA)  registry confirms an increased incidence of KS, skin cancers and, and non-
Hodgkin’s lymphoma ( NHL) among the renal transplant recipients, compared to the non-
transplanted population [29]. A retrospective study from  Ireland between 1994 and 2001 
showed skin cancer and Kaposi sarcoma to be more prevalent among the renal transplant 
recipients, compared to the normal population [30]. 
 Table 1.2 below summarises the incidence of PTM in different parts of the world and shows 
the most prevalent PTM in the respective regions. 
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Table 1.2 –Summary of PTM in the World 
Region Incidence of PTM Most Common PTM 
Africa – South Africa 
               
               Egypt              
3.4- 8.1% 
 
3.97%% 
Skin cancer and KS [17-20, 
31] 
Kaposi sarcoma [23] 
Middle East (MESOT) 0.75% -2.17% Kaposi Sarcoma 
Skin cancers [10, 15] 
Europe – (Portugal; 
United Kingdom) 
1.6 %-3.5% Colorectal cancer- Lymphoma  
[32] 
Asia (Korea, Taiwan, 
India) 
1.8 % - 8.4% PTLD; renal and gastric 
cancers [12, 24-26] 
America (Cincinnati 
Transplant Tumor 
Registry –CTTR) 
6-8% PTLD; Squamous carcinoma 
of the lip; cervix; skin; vulva 
[11]. 
Australia 6.3-12% Skin cancer [28] 
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1.2.3  Spectrum of Cancers in Post-transplant recipients 
 Skin cancers  
Skin cancers have been noted in most studies from renal transplant units to be the most 
common cancer worldwide among the Caucasian population [7, 19, 31]. Non-melanoma skin 
cancers are the commonest, of which squamous cell carcinoma is the most prevalent 
subtype among renal transplant recipients, whilst in the non-transplanted population, basal 
cell carcinoma is the most prevalent [5, 11]. In this population group, skin cancers occur at a 
younger age, are more aggressive, have an increased risk of metastasis and recurrence 
after treatment [7]. Melanomas and Merkel’s cell carcinoma also more commonly occur in 
these immunosuppressed patients compared to the normal population [11].  
 Kaposi Sarcoma (KS) 
Kaposi sarcoma is a common malignancy among immunocompromised patients. It is one of 
the three common PTMs reported in the literature, together with skin and PTLD. The risk of 
developing KS is 500 times more in the post-transplant population compared to the non-
transplanted population [33].Kaposi sarcoma is most common among males, patients 
exposed to cyclosporine and azathioprine, and people of Mediterranean origin[2, 33, 34]. In 
retrospective studies from South Africa, KS was shown to have an incidence of  6% in 
Johannesburg and 3.4% in Cape Town [18, 21]. 
Kaposi sarcoma is a tumour of the blood vessels that is usually seen as hyper-pigmented 
skin lesions although  at times, it presents with disseminated disease, which carries  a high 
mortality [2]. Common sites of dissemination are the mouth, mucous membranes, lungs, 
lymphoid tissue and the gut. Histology shows a proliferation of endothelium-derived spindle 
cells. Human herpes virus-8 is known to cause KS, but a prospective study in France found 
no difference in survival or risk of graft loss in recipients who were seropositive for HHV8 
pre-transplant [2, 33, 35].  
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Post-Transplant Lymphoproliferative Disorder (PTLD) 
This post-transplant lymphoproliferative disorder is a heterogeneous group of malignancies 
that arises as a result of lymphoid proliferation in recipients of a solid organ transplant in the 
presence of immunosuppression  [26]. These lymphoproliferative disorders are Epstein-Barr 
virus (EBV)  associated in 80% of cases in transplant recipients [36] Posttransplant 
lymphoproliferative disorder is the second most common PTM after skin cancer [10]. The 
incidence of PTLD is highest within the first year of transplantation and falls progressively 
with time from transplantation [7].This is postulated to be as a result of the high doses of 
immunosuppressants and anti-lymphocyte treatment given during the 1st year post 
transplantation.  Post-transplant lymphoproliferative disorder in renal transplant recipients is 
usually NHL with extra nodal involvement and is usually of the large B-cell subtype [5, 10, 
37]. 
The World Health Organisation (WHO) has classified these lymphoproliferative diseases into 
three categories based on cytogenetics, clonality, and genetic rearrangements. Table 1.3 
shows the most recent classification released in 2008. 
 
 
 
 
 
 
 
 
9 
 
Table 1.3 - World Health Organisation classification of PTLD 
Category  
Early lesions    Reactive plasmacytic hyperplasia  
Infectious mononucleosis-like lesion 
Polymorphic PTLD  
Monomorphic PTLD B-cell lymphomas 
            Diffuse large B-cell lymphoma 
             Burkitt lymphoma 
             Plasma cell myeloma 
             Plasmacytoma-like lesions 
 
T-cell lymphomas 
             Peripheral T-cell lymphoma 
             Hepatosplenic T-cell lymphoma 
 
Classical Hodgkin lymphoma –type 
PTLD 
 
 
Reproduced with permission from the publisher [36] 
  
Solid tumours 
 These are not as common as skin cancers and KS but have been shown to be more 
prevalent in the renal transplant population as compared to the normal population. They 
have been described in all organs and tend to be more aggressive with increased mortality 
[38]. The risk of breast cancer in post -transplant recipients is lower than the normal 
population [10]. 
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1.2.4  Risk Factors for developing a Post -Transplant Malignancy 
Since the first renal transplant in 1956, various risk factors have been associated with the 
development of PTM in the different continents [9]. The role of immunosuppressant’s 
appears to be pivotal in the development of PTM coupled with other risk factors [28, 39]. A 
number of risk factors are implicated in the development of each of the various types of 
malignancies encountered in the post renal transplant period. 
Table 1.4 below summarises the risk factors associated with the common PTM described to 
date.  
Table 1.4 - Summary of the risk factors for developing PTM (compiled from Sheik et al. [11] 
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Cancer Risk Factors 
Skin  
 
Older age at transplantation 
Increasing time from transplantation  
Gender: Male 
Race: Caucasian 
HLA A11; B27; DR7 
Human Papillomavirus (HPV) infection 
Use of cyclosporine (CYA), azathioprine, corticosteroids[2] 
Sun exposure -ultraviolet radiation[2] 
Geographic location 
CD4 lymphopenia [2] 
Kaposi Sarcoma Geographic location – Africa, the Mediterranean, the Caribbean 
and the Levant 
Human Herpesvirus (HHV) 8 infection [2]  
Epstein-Barr Virus (EBV) infection 
Hyperpigmented skin 
PTLD EBV is associated with Hodgkin’s Disease and NHL [2] 
Cytomegalovirus(CMV) infection in the donor graft 
Polyclonal  or monoclonal antibodies [2] 
OKT3 antibody and anti-thymocyte globulin(ATG) 
Cyclosporine 
Solid Organ Traditional risk factors such as:  
            smoking 
            genetic predisposition 
            family history 
Older age at the time of transplantation 
Race: Caucasians 
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1 Immunosuppressant Drugs 
The immunosuppressant drugs used post organ transplantation are a double-edged sword in 
that they are crucial in preventing graft rejection, but also pose a high risk for developing a 
malignancy. The risk for malignancy posed by immunosuppressant drugs has been shown to 
be related to the following factors. 
a). Type of Drug  
Azathioprine and MMF are anti-metabolites that are used for induction and maintenance 
therapy post renal transplantation. Mycophenolate mofetil is associated with a reduction in 
acute rejection and an increase in graft survival. Meta -analysis of the research done on the 
effects of these two drugs on PTM show that MMF has anti-proliferative activity against 
lymphomas and leukaemias [6].Maintenance therapy with MMF was associated with 
significantly reduced risk of PTLD compared with azathioprine[6, 7]. 
The antibody therapies used as induction treatment and in the management of rejection, are 
associated with an increased incidence of PTLD [6].The depleting anti -T cell antibodies 
(muronomab CD3 and ATG) are associated with an increased risk of all cancers in the post-
transplant recipients when compared to the recipients who received the non-lymphocyte 
depleting agent, basiliximab (IL-2 receptor antagonist) [6]. Muronomab is no longer used in 
induction therapy as it is no longer manufactured. According to the findings from ANZDATA, 
the use of depleting anti-lymphocyte antibodies is associated with an increased incidence of 
skin cancers especially  non melanomas[2, 7]. Recent collaborative studies have shown an 
increased incidence of lymphomas, non-melanoma skin cancers, carcinoma of the cervix, 
vulva and vagina[7] 
The use of corticosteroids was noted to be associated with an increased incidence of basal 
cell and SCC in a population-based study of prescriptions for steroids [6].Corticosteroids are 
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never used alone in the management of post-transplant recipients hence its effect on PTM is 
difficult to elucidate. 
 Calcineurin inhibitors (CNIs),were introduced in the 1980s and they brought a drastic 
reduction in acute graft rejection [39].   Azathioprine and CYA are associated with an 
increased incidence of skin cancers, lymphomas, KS, breast cancer, brain tumours and 
bladder cancers while the use of MMF and tacrolimus has been shown to be protective of 
PTM in most meta-analysis of studies done to date [1, 8, 33]. 
Sirolimus (rapamycin), an M-TOR-I (mammalian target of rapamycin -inhibitor), is associated 
with a decrease in the incidence of KS, and its regression in post renal transplant recipients 
[7, 33, 40]. 
b). The dose  
Retrospective and prospective studies have shown that heart transplant recipients are at a 
higher risk of PTM compared to renal allograft recipients because they receive higher doses 
of immunosuppressants [5]. The risk of developing PTLD is most significant during the first 
year post-transplantation as the doses of immunosuppressants are at their highest and 
monoclonal and polyclonal antibodies are used for induction during this period [5, 10]. Dantal 
et al. showed in their randomized comparative study that increasing the dose of CYA is 
associated with an increase in the risk of malignancy but decreasing the dose predisposed 
the recipient to rejection [41]. 
c). Duration of exposure 
The higher the cumulative time of exposure to immunosuppressants the greater the risk of 
PTM [6].This then poses a challenge as the goal of the transplant nephrologists is to ensure 
many years of graft survival.  
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2. Oncogenic Viruses 
There are 3 possible routes of infection with oncogenic viruses:  
a). From the donor 
b). Re-activation of latent infection in the recipient 
c). De novo infection in the recipient [6, 12]. 
Kaposi Sarcoma is strongly associated with HHV8. Human Herpes Virus 8 is also associated 
with multiple myeloma. A study from France showed that infection with HHV8 is not a 
contraindication to renal transplantation as the risk of developing an HHV8 infection, and 
ultimately KS is very low [35].Kaposi sarcoma has been predominantly seen in the black 
transplant population and in regions with high sero prevalence of HHV8 which include sub 
Saharan Africa. The areas in Europe and America were such epidemiological studies have 
been done have had much lower sero prevalence of HHV8.In SA HHV8 sero prevalence in 
blood donors showed higher levels in the blacks compared to the Caucasians [21]. 
 Epstein-Barr virus has been linked to the development of PTLD, nasopharyngeal cancers 
and leiomyosarcomas. Human Papillomavirus is associated with squamous cell carcinoma 
of the skin, cervix, anus, mouth, vagina, penis and Bowen’s disease [6].Hepatitis B and C 
viruses are linked to hepatocellular carcinoma [6]. Donors and recipients are usually 
screened for Hepatitis B and C before surgery and vaccination given for Hepatitis B to the 
recipient if they are negative. 
Cytomegalovirus (CMV) is associated with PTLD but y since the 1990s CMV prophylaxis has 
become standard of care. This saw a drastic reduction in the incidence of CMV disease in 
transplant recipients as observed at CMJAH in a review of the transplant registry between 
2000 and November 2004[42]. . 
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Human Immunodeficiency Virus (HIV) is an oncogenic virus that was discovered in the early 
1980s, and currently, some centres offer renal transplantation for virally suppressed patients 
on antiretroviral therapy. HIV is associated with various cancers which include KS, 
squamous cell carcinoma, lymphomas and an increased incidence of solid organ cancers. 
To date, no study has reported the impact of HIV infection on the development of PTM in 
transplanted patients. 
 Human Papillomavirus serotypes 16 and 18 are  associated with epithelial cancers of the 
skin, cervix, penis and the anogenital area in post-transplant recipients[12].The human 
polyomavirus has recently been implicated in tumourigenesis through the transformation of 
somatic cells. The associated malignancy is a skin cancer called Merkel cell carcinoma [12]. 
3.  Environmental Factors 
Skin cancers are mainly seen in the Caucasian population with higher incidences being seen 
in the temperate climates of Australia, Africa, and America. Kaposi sarcoma tends to occur 
in geographic areas in which HHV8 is an endemic infection; these areas include Africa, the 
Mediterranean, the Caribbean, and the Levant. The descendants of populations originating 
in these regions living in other locations are also at increased risk of KS [7]. 
4. Traditional Factors 
These are not unique to the transplant population alone. They include advanced age, 
smoking, analgesic abuse, race and a genetic predisposition to malignancy [12]. Skin 
cancers are more prevalent in older male recipients who are Caucasian and above 50yrs of 
age [2, 7, 8, 22].   
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1.2.5  Pathophysiology of PTM 
The theories related to the pathogenesis of PTM are varied, and no one process can explain 
the increased incidence of malignancy in this population of patients. The most likely scenario 
is an interplay of these various mechanisms on a background of individual recipient and 
geographically-related environmental risk factors seen in the different patients and 
environmental factors as posed by the varied geographical locations [2].Below is a 
discussion of the various mechanisms that have been postulated to result in malignancy in 
the post-transplant population. 
Immune Paresis 
The immunosuppressant drugs prescribed to renal transplant recipients result in immune 
paresis to varying extents [6]. The depressed immune system  increases  recipient 
vulnerability to infections allows for the reactivation of latent infections and  creates an 
environment that allows the oncogenic virus to thrive [5]. The paralysed T cell-mediated 
immune response fails to rid the body of virally infected cells and allows the incorporation of 
oncogenic viral genes into host DNA resulting in abnormal cell proliferation. Such processes 
have been implicated in   EBV-associated PTLD and HHV 8-related KS [10, 12]. 
 The weakened T cell-mediated immune response then provides poor tumour surveillance 
and thus allowing tumour growth to continue unchecked.  The host of cancerous cells allows 
for uncontrolled cell division with the failure of the processes involved in apoptosis. 
Corticosteroids and cyclosporine are pro–oncogenic and have also been shown to decrease 
tumour surveillance [12, 43]. Cyclosporine and Azathioprine impair the ability of the body to 
repair damaged  DNA [6]. 
The use of immunosuppressive drugs has been seen to increase the proliferation of growth 
promoting cytokines such as TGF-B1; VEGF; IL-10 and their receptors. In animal studies, 
cyclosporine was seen to increase angiogenesis and facilitate tumour growth through the 
increased release of VEGF and TGF-B from activated lymphocytes [43]. However, studies 
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by Gallagher et al. show no increase in malignancy in patients on CNIs [1].m-TOR-I  ( 
sirolimus and everolimus ) have been shown to regress tumour growth by decreasing the 
transcription enzyme p70 S6 kinase, IL-10, cyclins and VEGF from lymphocytes [7]. The 
anti-proliferative properties of sirolimus were shown in the study by Campistol et al. on 
patients with KS [40]. 
Prolonged Uraemia 
Chronic uraemia is an immune suppressing state and most patients on RRT awaiting renal 
transplantation have urea levels above normal despite dialysis. A multicentre study in the 
United States of America (USA), Europe, Australia and New Zealand showed that patients 
on dialysis had an increased incidence  of developing malignancy compared to the non-
transplanted population [44]. Increased duration of dialysis before renal transplantation, 
female sex, and younger age group have been linked to cancers of the kidney and the 
urogenital system in dialysis patients. The mode of dialysis appears not to affect the risk of 
malignancy [6, 44]. 
Environmental Factors 
Ultraviolet light destroys DNA and disrupts the DNA repair mechanisms in cells. The 
damaged DNA forms thymidine dimers which lead to inactivation of the tumour suppressor 
gene p53 [12].This is a strong risk factor in the development of skin cancer with both pre and 
post-transplant exposure to sunlight being significant [7]. The interplay of UV radiation, white 
skin pigmentation, male gender, type of immunosuppressant used and the age of the patient 
ultimately determine the overall risk of skin malignancy. 
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1.2.6 Average time to diagnosis of PTM 
The interplay of various risk factors and different mechanisms of oncogenesis in the post 
renal transplant patients result in the development of PTM at different times post-transplant. 
The average time to diagnosis of cancer post renal transplantation is five years [10].The 
table below summarises the time frames to the diagnosis of various PTMs as observed in 
different studies.  
Table1.6 - Average Time to diagnosis of PTM 
Cancer Type Average time to diagnosis post-
transplant 
Skin 
Non-Melanoma 
 
 Melanoma 
4-9 years 
Eight years below 40 years and  
Three years in those above 60 years 
Not known[11] 
Post-Transplant Lymphoproliferative 
Disease (PTLD) 
Biphasic:  0-12 months 
               After 5years  [10] 
Kaposi Sarcoma (KS) 13-22 months [11] 
Solid Organ Not known 
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1.2.7 Outcome of patients with Post Transplant Malignancy 
Outcomes of PTM depend on the type of malignancy, histology and extent of disease at the 
time of diagnosis. In general PTMs are more aggressive and often have metastasised by the 
time of diagnosis [11, 45]. These factors result in poor survival rates of 25-35% and very 
high mortality rates , especially in PTLD and solid organ malignancies [12]. Metastatic 
disease at presentation is usually associated with high mortality rates. 
Management of KS and PTLD in renal transplant recipients involves various modalities, 
though the universal approach is to decrease the dose of the immunosuppressants and/or 
change to a regime with decreased risk of PTM e.g. sirolimus, tacrolimus, MMF [7, 45]. A 
change of immunosuppressant to sirolimus has been shown to regress the lesions of KS 
[33]. Dose reduction is an effective treatment modality in recipients with PTLD and KS [12, 
45]. Excision of localized KS lesions, radiotherapy, laser, and chemotherapy, especially for 
disseminated disease, usually results in disease remission [34].. Most types of PTLD are 
sensitive to chemotherapy, though the challenge is reducing chemotherapy-related toxicity. 
Current recommendations favour rituximab over CHOP ( cyclophosphamide, doxorubicin, 
vincristine, and prednisone) [45].  
Most skin cancers are diagnosed early and respond to excision and immunosuppressant 
dose reduction [13]. The challenge with dose reduction is the risk of rejection. The therapies 
for skin cancer include photodynamic therapy, cryotherapy, superficial ablative therapy and 
Moh’s micrographic surgery [45]. 
 A combination of surgery and chemotherapy has been employed successfully with solid 
organ cancers and lymphomas [12].  
1.2.8  Prevention of Post-Transplant Malignancy 
The risk of developing a post-transplant malignancy is inherent in every recipient and 
measures must always be taken to prevent these cancers throughout the recipient’s life. 
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Many transplant nephrologists have suggested various steps both pre and post-transplant 
have been suggested to reduce morbidity and mortality from post-transplant malignancy 
among these patients.  
Recommended Pre-transplant Measures 
These measures are targeted at the risk factors for developing PTM.  
Table 1.7 below summarises these measures. 
Table 1.7 – Measures to reduce PTM Pre-Transplant 
Risk Factor Possible Intervention 
Age Avoid transplanting patients above 65 years of age 
Sex Screen for malignancy related to sex e.g. prostate, cervix, breast 
Obesity Avoid transplanting patients with BMIs above 35 
Oncogenic Viruses Screen, prevent and treat for oncogenic viruses in donors and 
recipients [6] 
     
Premalignant 
lesions 
Screen and treat for e.g. CIN, hyperkeratosis, renal cysts [5] 
Previous 
diagnosis of 
cancer 
Transplantation must be delayed for two years after remission of 
cancer[12] 
  
The challenge with pre-transplant screening is most patients remain on the  waiting list for 
many years and , some patients may be transplanted with pre-malignant lesions or may 
contract oncogenic viruses while waiting [12]. 
Table 1.8 below summarises the recommended post-transplant measures that should be 
taken to prevent PTM.  
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Table 1.8- Recommended Screening for Post-Transplant Malignancy 
Cancer Demography Recommendations 
Breast Women > 50 years Mammogram every 1-2 years 
 
 Women <50 years at high risk 
(family history or prior cancer) 
Mammogram every 1-2 years  
 
 
Cervical/Uterine/
peri-anal 
Women >18years Annual gynaecological examination and 
pap smear 
Prostate Men >40years Rectal exam and PSA every year  
Colorectal Recipients > 50 years Faecal blood test yearly  
 Flexible sigmoidoscopy every five years 
Skin and KS All recipients 
 
High risk of skin cancer 
Low risk 
Annual self-exam and biopsy of all 
suspicious lesions 
Six monthly dermatologist examination 
Annual examination by dermatologist 
Routine use of sunscreens and reducing 
sun exposure. 
PTLD All ages Three monthly history and examination for 
feature of PTLD –in the first year of 
transplantation 
Annually intervals after the 1st year [12] 
Carriers of Hep 
B or C virus 
All ages Annual alpha-fetoprotein level and 
abdominal sonar 
Table is adapted from Morath et al. and Kasiske et al. [12, 46] 
Immunosuppressant drugs should be kept at a minimum number and at a dosage to achieve 
normal graft function without rejection and with minimal side effects. Drugs with low potential 
to tumour genesis e.g. m-TOR inhibitors can be considered [2] 
22 
 
1.3  RATIONALE OF THE STUDY 
This study was conducted as a follow-up to the work of Margolius in which PTM in renal 
transplant recipients between August 1966 and November 1989 at Charlotte Maxeke 
Johannesburg Academic Hospital (CMAJH) was reviewed [18, 31]. This current study will 
allow us to compare the findings of the two unique transplant eras and thus evaluate the 
effects of immunosuppressants and the different risk factors posed by the various 
demographic factors in the two periods, as described below.  
This study reviews malignancies post renal transplant in patients transplanted in the era 
1990 to 2010.This is a post-apartheid era in South Africa (SA) where the healthcare delivery 
system was improved and extended to the previously marginalised majority (non-white 
population -Indians, Blacks, and Mixed race). Thus, this study will include a more diverse 
group of transplant recipients which is more representative of the SA population. Literature 
strongly supports the theory that PTMs are related to immunosuppressant drugs and their 
total dose exposure in recipients. It is postulated that the current regimens are more potent 
and have increased the risk of PTM. Immunosuppressants used post renal transplantation 
have changed over the years, with steroids remaining in use since 1966 to the current day, 
albeit at lower doses for maintenance at CMJAH. Azathioprine, steroids, cyclosporine and a 
monoclonal antibody OKT3 were the drugs used before 1990 for induction and maintenance 
therapy. Since 1990 azathioprine has been replaced by MMF. Tacrolimus and sirolimus 
were introduced into the maintenance treatment of recipients of renal grafts in 1999 at 
CMJAH.  Antibodies against Interleukin 2 (IL-2) receptors were introduced in 1999 for 
induction.  
Most of the currently available literature is based on Asian, European, American, Australian 
and Middle East studies from the last decade whose demographic, environmental and 
carcinogenic exposures are different to those found in southern Africa.  
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The CMJAH renal transplant cohort has a significant population size and fairly well kept 
patient records which provide for a good data source to undertake this review. These 
patients have been followed up for a long enough period- 20years in this study- which is 
adequate to enable us to describe PTM in this cohort. 
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1.4  AIMS AND OBJECTIVES OF THE STUDY 
This study seeks to assess the extent to which PTM have affected renal transplant patients 
in the last 20 years and to identify the possible risk factors in comparison to previous reports 
locally and internationally. This will assist in improving patient care and thus reduce the 
number of recipients dying of malignancy with functioning grafts at CMJAH. 
Objectives 
1. Describe the incidence of malignancy among the renal transplant recipients during the   
study period. 
2. To determine the time from transplantation to diagnosis of cancer. 
3. To investigate the association between immunosuppressive regimens and risk of PTM. 
4. To identify other risk factors for developing PTM. 
5. To characterize the histological features of the different cancers in the study cohort. 
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2. CHAPTER 2- METHODS 
2.1  STUDY DESIGN 
This was a retrospective chart review of renal transplant recipients transplanted between 
01/01/1990 and 31/12/2010. 
2.2  STUDY SITE 
The study was conducted at CMJAH in the renal transplant unit. CMJAH is a quaternary 
academic hospital in central Johannesburg, SA. It is one of 6 centres in SA offering renal 
transplantation in the public sector.   
2.3  STUDY POPULATION AND SAMPLE 
The study population included all patients transplanted at CMJAH during the study period: 
1990-2010.The study sample includes all recipients who developed a PTM during the study 
period. 
2.4  ETHICAL APPROVAL 
Ethical approval was granted by the University of the Witwatersrand Human Research Ethics 
Committee (Medical) protocol number M120642 (Appendix A) 
2.5  ELIGIBILITY CRITERIA FOR THE RENAL PROGRAMME 
The CMJAH transplant unit has standard guidelines on eligibility criteria for renal transplant 
recipients. These guidelines exclude patients with malignancy and other risk factors for 
malignancy such as active Hepatitis B and C. These pre -transplant selection criteria ensure 
that patients who are transplanted have very low-risk profiles for the development of 
malignancy.  
 
 
26 
 
Inclusion criteria 
All patients are transplanted between 01/01/1990 and 31/12/2010 and above 18 years of 
age at that time of transplantation.  
Exclusion criteria 
1. All recipients who died; transferred or rejected within six months of transplantation. 
2. Recipients transferred in from other centres after transplantation. 
2.6  STUDY VARIABLES 
1. Age at the time of transplantation 
2. Gender 
3. Ethnicity /Race 
4. Aetiology of ESRD 
5. Source of the graft 
6. Number of grafts received 
6. Mode of dialysis and duration on dialysis before transplantation 
7. Immunosuppressant exposure history 
8. Oncogenic viruses diagnosed post-transplant 
10. Number of times the patient was treated for rejection 
11. Outcome of the recipient 
12. Malignancy diagnosed 
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13. Features of malignancy from histology reports 
         i. Histological findings 
         ii. Sites of metastases 
14.Duration from transplant to diagnosis of cancer 
2.7  DATA HANDLING AND ANALYSIS 
Recipient information was collected from each patient file onto a data collection sheet 
created on Epi Info version 3.4.3. (See Appendix C). Each recipient was given a unique 
study number linked to their file. The study numbers and recipient file numbers were kept 
separately. Data was analysed using STATA version 13. 
2.7.1  Descriptive analysis 
The demographic and clinical characteristics of all renal transplant recipients, of those who 
did not develop PTM and those who developed PTM, were described using proportions for 
categorical variables and mean and standard deviation for continuous variables (Table 1).  
Student t-test was used to compare mean age at transplantation for those who developed 
PTM with that of those who did not. The spectrum of PTM was described using a bar chart 
for all recipients and males and females (Figure 3.1). Time to cancer diagnosis was 
described regarding mean and standard deviation for specific cancers (Table 3.4). The p –
value was set at 0.05 for significance testing. 
  2.7.2  Cancer Incidence Analyses 
Time-to-event analysis was the primary method of analysis. Time started to the date of 
transplantation and ended in the last month of follow-up (measured as the last date of 
receipt of prednisone) or date of cancer diagnosis, or 31 December 2010 (date of database 
closure), whichever came first. 
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A cancer event was defined as the first cancer diagnosis made from the date of 
transplantation. Cancer incidence was calculated by dividing the number of cancer events by 
the person-time and reported per 100 000 person-years. Kaplan-Meier curves were plotted 
to show cumulative cancer incidence in males and females. 
Cancer incidence was also calculated by dividing the number of first cancer events by some 
renal transplant recipients and expressed as a percentage to allow for comparability with the 
Margolius study. 
2.8  RISK FACTOR ANALYSIS 
Unadjusted and adjusted Cox proportional hazards models were fitted to identify factors 
associated with the development of PTM in renal allograft recipients. 
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3. CHAPTER 3 - RESULTS 
 A total 959 patient records were reviewed, and 281 records were excluded as they did not 
meet the inclusion criteria of this study, 668 records were therefore considered for statistical 
analysis for this research report. 
3.1 DESCRIPTIVE SUMMARY OF THE DEMOGRAPHIC STATISTICS 
Table 1A- Summary of Descriptive Characteristics (Demographic data) 
Variable All Recipients No PTM PTM p-value 
Demographic  
Characteristics 
 n= 668 
% (n) 
n = 621 
% (n) 
n =47 
% (n) 
 
Sex 
Females 
Males 
 
36.8 (246) 
63.2 (422) 
 
37.2 (231) 
62.8 (390) 
 
31.9(15) 
68.1(32) 
 
0.469 
Ethnicity 
Black 
Caucasian 
Indian 
Mixed race 
 
50.6 (338) 
41.0 (274) 
  6.1 (41) 
  2.3 (15) 
 
(51.9)322 
(39.3)244 
(6.4)40 
(2.4)15 
 
34.0(16) 
63.8(30) 
 2.1 (1) 
0 
 
 
0.014 
 
Year of Transplantation 
1990-1995 
1996-2000 
2001-2005 
2006-2010 
 
275 (41.2) 
141 (21.1) 
142 (21.3) 
110 (16.5) 
 
235(37.8) 
139(22.4) 
139(22.4) 
108(17.4) 
 
40(85.1) 
2(4.3) 
3(6.4) 
2 (4.3) 
 
 
<0.001 
Age at Transplantation 
Males 
Female 
Overall  
Mean (S.D) 
37.4 (12.5) 
35.6 (12.1) 
36.7 (12.4) 
 
36.9 (12.5) 
35.2 (12.2) 
36.3 (12.4) 
 
42.9(11.6) 
42.8 (7.5) 
42.9 (10.4) 
 
0.009 
0.003 
0.001 
 
n= number; PTM-Post transplant malignancy 
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Table 1B- Summary of Descriptive Characteristics (Clinical Variables) 
Variable All Recipients Non PTM PTM P value 
Clinical Characteristics n =668 n=621 n=47  
Source of Graft 
Cadaver 
RLD 
NRLD 
Missing data 
 
505 (75.6) 
138 (20.7) 
23 (3.4) 
2  (0.3) 
 
466(75.3) 
130(21.0) 
23 (3.7) 
 
 
39 (83.0) 
8 (17.0) 
 
 
0.412 
Number of Grafts 
received  
   1 
   2 
  >3 
Missing data 
 
609 (91.2) 
27   (4.0) 
9     (1.4) 
23   (3.4) 
 
567 (91.3) 
24 (3.9) 
9(1.50 
21 (3.4) 
 
42 (89.4) 
3 (6.4) 
 
2 (4.3) 
 
 
 
0.499 
Number Rejection 
Treatments 
 0 
 1 
 2 
>3 
 
 
498 (74.6) 
135 (20.2) 
29   (4.3) 
6     (0.9) 
 
 
455 (73.3) 
132 (21.3) 
28 (4.5) 
6 (0.9) 
 
 
43 (91.5) 
3 (6.4) 
1 (2.1) 
 
 
0.043 
Aetiology ESRD 
Hypertension 
Diabetes Mellitus 
APCKD 
Glomerulonephritis 
Ig A Nephropathy 
Analgesic Nephropathy 
Reflux Nephropathy 
Other 
Missing data 
 
220 ( 32.9 ) 
29   (4.3 ) 
22   (3.3 ) 
96   (14.4 ) 
8     (1.2 )  
13   (1.9) 
37   (5.5) 
111 (16.6) 
132 (19.8) 
 
202 (32.5) 
29 (4.7) 
17 (2.7) 
87 (14.0) 
7 (1.1) 
12 (1.9) 
37 (6.0) 
99 (15.9) 
131 (21.1) 
 
18 (38.3) 
0 
5 (10.6) 
9 (19.2) 
1 (2.1) 
1 (2.1) 
0 
12 (25.5) 
 
 
 
 
0.048 
Mode of dialysis 
Haemodialysis 
Peritoneal Dialysis 
Both 
Missing data 
 
103 (15.4) 
133 (19.9) 
15   (2.3) 
417 (62.4) 
 
103 (16.6) 
126 (20.3) 
14   (2.3) 
378 (60.9) 
 
0 
7   (14.9) 
1   (2.1) 
39 (83.0) 
 
 
0.021 
Oncogenic viruses 
Yes 
 
91   (13.6) 
 
 
87 (14.0) 
 
 
4 (8.5) 
 
 
0.203 
Types of virus 
diagnosed 
CMV 
HIV 
Hepatitis B 
Hepatitis C 
Other 
N=91 
 
65  (71.4) 
13  (14.2) 
8   (0.1) 
2    (0.02) 
4    (0.04) 
N=91 
 
63 (69.2) 
13 (14.2) 
8  (0.1) 
1 (0.01) 
3 (0.03) 
N=91 
 
2 0.02 
0 
0 
1 (0.01) 
1 (2.1)(0.01) 
 
 
0.039 
Outcome of patient 
Alive and in care 
Death 
Rejected 
Lost to follow up 
Transferred 
Missing data 
 
207 (30.9) 
182 (27.3) 
140 (20.9) 
86   (12.9) 
51   (7.6) 
2     (0.3) 
 
203 (32.7) 
159 (25.6) 
134 (21.6) 
76 (12.2) 
48 (7.7) 
1 (0.2) 
 
4   (8.5) 
23 (48.9) 
6   (12.8) 
10 (21.3) 
3   (6.4) 
1   (2.1) 
 
 
<0.001 
Immunosuppressants 
Azathioprine 
Cyclosporine 
Tacrolimus 
MMF 
Sirolimus 
 
428 (64.1)  
575 (86.1)  
93  (13.9) 
302 (45.2) 
114 (17.1)  
 
387 (62.3) 
529 (85.1)  
92 (14.8) 
291 (46.9)  
108 (17.4) 
 
41(87.2)  
46(97.9)  
1 (2.13) 
11 (23.4) 
6 (12.8) 
 
0.001 
0.006 
0.006 
0.002 
0.0416 
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The study population had more males than females and among those who developed a 
malignancy, 68.1% were males. Overall the age at transplantation was 36.7 years but the 
recipients who developed a malignancy were older at transplantation with an average age of 
42.9 years old (p= 0.001).  
This cohort of renal transplant recipients comprised predominantly of Blacks and Caucasians 
who contributed 50.6% and 41.0% respectively; the Indian and the mixed race recipients 
formed 8.4% of the study population. Of those who developed a PTM, 63.8% were 
Caucasian while 34% were blacks and no mixed race recipients developed cancer 
(p=0.014).  
The number of patients transplanted between 1990 and 2010 decreased gradually over the 
20 years of the study with the highest number of renal transplants occurring during the 
period 1990-1995 (41.2%), and the least between 2006-2010 (16. 5%).Most of the recipients 
who developed a PTM were transplanted between1990-1995 (85.1%), and this was 
statistically significant (p=<0.001). 
The commonest source of renal grafts was from cadaveric donors (75.6%). Thirty- nine of 
the 47 recipients who developed a malignancy received their grafts from cadaveric donors 
compared to   17% of recipients of RLD grafts who developed PTM were linked to RLD 
grafts (p=0.412). No cancer was diagnosed in NRLD recipients.  
In this cohort, 91.2% of the recipients were transplanted once, and 74.6% were never 
treated for rejection. Among those who developed cancer, 10.7% received two or more 
grafts and 8.5% were treated for rejection.  
Hypertension and glomerulonephritis were the commonest causes of end-stage renal 
disease in this population. The aetiology of renal failure was not documented in almost 20% 
of the files and 16.6% was captured as “other”. The conditions under the category “other” 
included congenital causes and unknown aetiology. Among the recipients who had ADPKD 
and analgesic nephropathy as an aetiological factor, 12.7% of them developed a 
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malignancy. A quarter of the recipients whose aetiology was documented as “other” 
developed a malignancy. No transplant recipient whose cause of renal failure was diabetes 
mellitus (DM) or reflux nephropathy or missing developed cancer. 
The mode of dialysis the recipients were on before transplantation was poorly documented 
in the files with 62.4% of the records having no documentation of this variable. The mode of 
dialysis is unknown in 83% of those who developed a PTM.  
Oncogenic viruses were not present in 84.1% of the study population and of the recipients 
who had an oncogenic virus, four developed cancer. The viruses diagnosed were CMV, 
Hepatitis B and C and HIV. 
A third of the recipients are still alive and in care while 69% of the cohort had adverse 
outcomes. 
3.2  SPECTRUM OF PTM AT CMJAH 
The bar graph below summarises the spectrum of malignancies diagnosed among the 
recipients or renal transplants at CMJAH in the era under review. The cancers are shown 
about gender. 
Figure 3.1 Spectrum of PTM at CMJAH 
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Skin cancers (SCC, BCC, other skin cancers, melanoma) are the commonest type of PTM at 
CMJAH contributing 44.7% of the cancers. Non-melanomas are more predominant while 
squamous cell carcinoma is the most prevalent histological diagnosis among the recipients 
who developed skin cancers. More males than females are affected by skin cancer in this 
cohort. Of the 13 recipients who had analgesic nephropathy as the aetiology of ESRD, one 
recipient developed skin cancer. 
Kaposi Sarcoma is the second commonest cancer affecting 23.4% of the recipients and was 
seen mostly in black male recipients. Two recipients who self-identified themselves as 
Caucasian had KS. 
Post-transplant Lymphoproliferative Disorder comprised mainly of lymphomas and 
leukaemias with a ratio of 4 males to 3 females. The one Indian recipient who developed a 
malignancy had a lymphoma. 
Anal cancer, breast, and cervical carcinoma were seen in females only while the renal 
cancers were diagnosed in 3 black males. 
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3.3 HISTOLOGICAL CHARACTERISTICS OF THE CANCERS DIAGNOSED AT CMJAH 
Table 2 below shows the histological diagnosis of the four main classes of cancers 
diagnosed in this cohort. 
Table 2 – Histological Characteristics of the Cancers diagnosed at CMJAH 
Type Histological Diagnosis Frequency 
n=47 
Incidence 
Skin 
 
n=21 
Melanoma 
Basal Cell carcinoma 
Squamous cell carcinoma 
Unspecified 
3 
4 
10 
4 
4.97/1000 
(CI 3.21-7.70) 
KS 
n=11 
Disseminated KS 
Localised KS 
7 
4 
2.73/1000 
(CI 1.51-4.92) 
PTLD 
 
 
n=7 
Large B cell NHL 
T cell lymphoma 
Refractory anemia blasts in 
transformation 
Acute Myeloid Leukaemia 
Chronic myeloid leukaemia 
3 
1 
1 
1 
1 
 
 
 
1.72/1000 
(CI 0.82-3.61) 
Solid 
Organ 
 
n=8 
Breast -Adenocarcinoma 
Prostate -Adenocarcinoma 
Kidney –Papillary renal cell 
carcinoma 
Anus 
CIN 
1 
2 
3 
1 
1 
 
 
1.97/1000 
(CI 0.99-3.95) 
n = number 
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 Seven of the eleven recipients diagnosed with KS had disseminated disease. One of the 
recipients had KS of the ureters, and he is still alive after chemotherapy and a switch to 
sirolimus. According to the information in the hospital records, none of the recipients with KS 
were ever tested for HHV 8 virus. 
Post-transplant lymphoproliferative disorder was diagnosed in 14.9% of the recipients who 
developed a malignancy and the histology was predominantly that of large B-cell NHL. One 
patient had a histological diagnosis of RAEB-T (refractory anemia with excess blasts in 
transformation) on bone marrow aspirate and trephine diagnosed in 1995.This is now 
considered as acute myeloid leukemia in the new WHO classification. Mortality was 100% 
among the recipients diagnosed with PTLD. All the recipients who developed PTLD were 
transplanted once, had never been treated for rejection and 
Solid organ malignancies were the least common type of PTM encountered. 
3.4  AVERAGE TIME TO DIAGNOSIS OF PTM  
Table 3 below summarises the average time from transplantation to diagnosis of cancer as 
calculated for this cohort.  
Table 3 – Average time to diagnosis of PTM 
Malignancy Median (Interquartile Range) years 
Skin 
    Melanoma 
    Basal Cell carcinoma 
    Squamous cell carcinoma 
7.3 (4.0 – 8.8) 
7.6 (2.8 – 10.5) 
7.6 (2.3 – 8.6) 
5.2 (3.4 – 7.8) 
Kaposi Sarcoma 2.1 (0.8 – 5.9)  
PTLD 3.8 (1.9 – 14.3) 
Solid Organ 
  
5.9 (4.1 – 11.9) 
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Kaposi Sarcoma was diagnosed earliest at median time of 2.1yearsyears post 
transplantation. Non-melanoma skin cancers were seen earlier than the melanomas with 
squamous cell carcinoma being diagnosed at a median time from transplantation of 5.2 
years. Solid organ cancers were diagnosed later at a median time of 5.9years post 
transplantation. 
3.5  INCIDENCE OF PTM AT CMAJH 
In this study, 47 recipients developed a post-transplant malignancy, and 668 recipients were 
included for statistical analysis. The incidence of malignancy at CMJAH during the study 
period 1990-2010 is 7.0 % (95% CI 5.2-9.4).  
The median follows up time was five years (IQR 2.0-8.6) and mean follow-up time was 5.9 
years (STD 4.9). 667 recipients were included in the incidence analysis and contributed to a 
total of 3997 person-years. Overall cancer incidence was 1176 (95% CI 883-1565) per 100 
000 person years. In males cancer incidence per 100 000 person-years was 1249 (CI 883-
1766) and in females, it was 1045 (CI 630-1733).  
Below is the Kaplan Meier curve summarizing the overall cancer incidence in this cohort. 
 
 
 
 
 
 
 
37 
 
Figure 3.2 Kaplan-Meier curve of the cumulative incidence after renal transplantation by 
gender 
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3.6 RISK FACTORS OF DEVELOPING PTM  
Table 4 – Univariate and Multivariate Analysis of the Risk factors of developing a PTM 
Characteristic Unadjusted HR 
(95%CI)  
P value Adjusted HR 
(95%CI) 
P value 
Age 1.06 (1.03 -1.08) <0.001 1.05 (1.03-1.08) <0.001 
Gender 
Female 
Male 
 
1 
1.12 (0.60 -2.08) 
 
 
0.720 
 
1 
1.35 (0.71-2.59) 
 
0.361 
Ethnicity 
Black 
Caucasian 
Mixed Race/Indian 
 
1 
1.77 (0.97-3.26) 
0.30 (0.04-2.25) 
 
 
0.064 
0.240 
  
Year of Transplant 
1990-1995 
1996-2000 
2001-2005 
2006 -2010 
 
1 
0.11 (0.03-0.45) 
0.19 (0.06-0.63) 
0.55 (0.13-2.40) 
 
 
0.002 
0.006 
 
0.424 
 
1 
0.12 (0.03-0.53) 
0.15 (0.02-1.28) 
0.51 (0.05-5.11) 
 
 
0.005 
0.083 
0.0566 
Graft Source 
Cadaver 
NRLD/RLD 
 
1 
0.53 (0.25-1.13) 
 
 
0.099 
  
No  of Grafts received 
  1 
>2 
 
1 
0.65 (0.19-2.19) 
 
 
0.488 
  
Ever treated for Rejection 
No 
Yes 
 
1 
0.38 (0.13-1.05) 
 
 
0.062 
  
A etiology 
Other 
Hypertension 
Glomerulonephritis 
 
1 
1.07 (0.56-2.05) 
1.27 (0.57-2.82) 
 
 
0.830 
0.557 
  
Oncogenic virus 
Yes 
 
0.68 (0.24-1.90) 
 
0.459 
  
Immunosuppressants 
Exposure 
 
Azathioprine 
 
Cyclosporine 
 
Tacrolimus 
 
MMF 
 
Sirolimus 
 
 
 
 
2.17 (0.90-5.19) 
 
5.49 (0.75-39.95) 
 
0.13 (0.02-0.98) 
 
0.35 (0.18-0.69) 
 
0.54 (0.23-1.26) 
 
 
 
0.083 
 
0.093 
 
0.0047 
 
0.002 
 
0.154 
 
 
 
0.39 (0.06-2.39) 
 
2.92(0.32-26.49) 
 
0.21 (0.02-2.01) 
 
0.58 (0.22-1.56) 
 
1.06 (0.38-2.97) 
 
 
 
0.307 
 
0.341 
 
0.176 
 
0.282 
 
0.915 
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We fitted unadjusted and adjusted Cox models to identify independent risk factors for cancer 
in renal transplant patients. Factors explored for their association with cancer in unadjusted 
analysis were age, gender, ethnicity, year of transplant, source of graft, number of grafts 
received, number of times the patient was treated for rejection, aetiology of renal disease, 
the presence of a diagnosed oncogenic virus and exposure to the immunosuppressant drugs 
azathioprine, cyclosporine, tacrolimus, MMF, and sirolimus. 
 In unadjusted analysis, increasing age was significantly associated with developing cancer. 
Patients transplanted in the period of transplant 1996-2000 and 2001-2005, had a lower risk 
of developing cancer than those transplanted in the period 1990-1995, HR 0.11 (0.03-0.45) 
and 0.19 (0.06-0.63) for 1996-2000 and 2001-2005, respectively. Patients who received the 
immunosuppressants tacrolimus HR 0.13 (0.02-0.98) and MMF HR 0.35 (0.18-0.69) had a 
lower risk of developing cancer compared to those who did not. 
The multivariable Cox model adjusted for age, gender, year of transplant and exposure to 
the immunosuppressant drugs azathioprine, cyclosporine, tacrolimus, MMF, and sirolimus. 
In adjusted analyses, the association of tacrolimus and MMF and cancer was lost. Age and 
the period of transplant were the only factors with a significant association with cancer.  
Older age at transplant predicted cancer development, with a 5% increase in the risk of 
cancer of each additional year of age at transplant, HR (1.05 (1.03-1.08). Patients 
transplanted in the period of transplant 1996-2000 had a lower risk of developing cancer 
than those transplanted in the period 1990-1995 HR 0.12 (0.03-0.53). 
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CHAPTER 4 -  DISCUSSION 
This study was conducted to assess the extent to which post-transplant malignancy affected 
the renal transplant recipients at CMJAH over 20years (1990-2010) and to compare the 
findings with the first 23 years (1969-1989) of renal transplantation at CMJAH, and with other 
centres or registries in the world.  
4.1        SPECTRUM AND HISTOLOGY OF MALIGNANCIES DIAGNOSED 
Skin cancer was most prevalent in this study contributing 44.7% of the malignancies 
reported and the non- melanoma types were more common with the histological diagnosis of 
squamous cell carcinoma being the most predominant. This is consistent with other studies 
reported in Cape Town and the other registries from the developed countries. [11, 22, 46] 
The number of Caucasians transplanted at CMJAH in the last 20 years has dropped 
significantly, but skin cancer remains the most prevalent malignancy. This suggests that the 
Caucasian population is at high risk for skin cancer. In the early 1980s, the routine use of UV 
light blockers was introduced as routine care to decrease the incidence of skin cancer which 
was 41.5/1000 transplanted cases [47]. In this study, the incidence has dropped to 
4.97/1000. 
 Pre-1990, KS was the 4th commonest cancer at CMJAH possibly because fewer blacks 
were previously transplanted, but with a doubling of the number of blacks transplanted in this 
study, it is now the 2nd commonest cancer. Other studies in Africa and Mediterranean areas 
have shown that KS is the second commonest PTM [15, 19, 21]. Kaposi sarcoma was 
diagnosed mostly in the non-Caucasian population in the studies done in Africa. In Cape 
Town Moosa et al found that most of the recipients who developed KS were of the mixed 
race group [21].From the MESOT registry, KS was the most predominant skin cancer with 
PTLD in the second position. In the developed world KS is not common. 
PTLD is the 3rd commonest PTM in the developing countries and the 2nd commonest in 
developed countries[10, 11]. In developing countries PTLD is seen mainly in the Indian 
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population and this is possibly so in the study done in Durban where PTLD and non-
melanoma skin cancers were equally common[20, 26]. The registries in the United States 
America and Europe show lymphomas to be the most predominant PTM in some centres 
while in others, it is second to skin cancer [48]. Presentation is usually in the early post-
transplant period and most recipients have extra nodal disease at diagnosis. 
Solid organ malignancy appears not to be common in the renal transplant population than 
that seen in the non-transplanted population[10, 15, 31]. Most studies in the developed and 
developing world have small numbers of recipients developing solid organ cancers. There is 
not much in the literature regarding these cancers. Some solid organ tumors in the post-
transplant population follows the pattern of the endemic cancers in the region e.g. bladder 
cancer in Egypt; gastrointestinal in Asian countries (Taiwan and Korea) [14, 24, 25] 
4.2  TIME FROM TRANSPLANTATION TO DIAGNOSIS OF PTM 
The risk of developing a malignancy increases with increasing time from transplantation. 
This has been confirmed in most studies on the risk of developing PTM [2, 6, 7, 12, 
31].Decreased mortality from infections and improved healthcare systems have seen 
patients surviving longer and the traditional risk factor for malignancy – age, becomes a 
significant risk factor. 
The time at which a PTM is diagnosed varies with the different cancers. KS seems to be 
diagnosed the earliest with a median time to diagnosis of 2.1 years ( IQR 0.8-5.9) in this 
study and has been diagnosed in other centres as early as 13 months after 
transplantation[11] . 
4.3  INCIDENCE OF PTM 
CMJAH 
The incidence of PTM at CMJAH between 1990 and 2010 was 7%. Margolius et al. found 
the incidence to be 7% between 1966 and 1989, and Disler et al. found the incidence to be 
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7.3% among the first 200 renal transplant recipients at CMJAH [18, 47].This may support the 
notion that the main risk factor for developing a malignancy is the overall 
immunosuppression in these patients from drugs and uraemia rather than specific drug 
classes [47]. 
Most researchers in the area of PTM have postulated the risk of PTM to rise in the 21st 
century, but this appears not to be the case at CMJAH given the findings from this review 
compared to the previous retrospective reviews at CMJAH[7]. This constant incidence of 
PTM at CMJAH could be due to the fact that the number of recipients exposed to the newer 
potentially more immunosuppressive drugs like MMF (45.2%); Sirolimus (17.1%), Tacrolimus 
(13.9%) is small compared to those on the older drugs Azathioprine (64.1%), cyclosporine 
(86.1%). The cumulative dose exposure of the newer drugs is also small in the era 1990-
2010. 
Africa  
The transplant centres in Africa that have conducted studies related to PTM are Egypt, 
South Africa (Johannesburg, Durban and Cape Town). In the study done by Maharaj and 
Assounga in Durban, with a mainly Indian population and sunny climate found that 5.4% of 
their recipients had PTM after an average follow up time of 12years; PTLD and skin cancer 
were the commonest[20]. 
The studies done in Cape town have incidences of PTM ranging from 3.35% to 7.56% and 
the recipients are mainly of the mixed race population[19]. Bakr et al found the incidence of 
PTM in their cohort of 95 recipients to be 3.97% and KS was the most common PTM among 
the recipients.  
MESOT 
The studies done in Iran and the findings from the MESOT registry show that the incidence 
of PTM in this region is lower than that found in our study and in western countries. [8, 11, 
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15].The incidence in some countries in this region are as low as 1.6% as reported in Iran[49]. 
The reasons why this is so being not clear but may be due to the fact that most grafts are not 
cadaveric and hence the amount of immunosuppression given is less. 
Western Counties 
In the western countries, the incidence of PTM is higher than that seen in the other regions 
in the world. Australia has the highest incidence with 26% being recorded in 2006 while in 
United Kingdom and US, the incidence are between 5-10%. Canada had an incidence of 
12.2% in 2002[19]. 
4.4  RISK FACTORS FOR DEVELOPING A PTM 
In this study, more males than females were transplanted and the average age at the time of 
transplantation was 36. 7years.Thus, the transplant recipients in this cohort were young. 
Recipients in the MESOT region especially Iran are mostly less than 30years of age[49]. 
The average number of patients transplanted per month decreased from about 5 to 2 in 
2010 due to a drop in donor availability. The study number reflects some selection bias as 
288 recipients were excluded from the study as they did not meet the inclusion criteria.  
Most recipients received their renal allograft from cadaveric donors, and 24.1% obtained 
them from RLD and NRLD. Cadavers are the most common source of grafts in most 
transplant centres in South Africa [31].  During the study period 1990 -2010, 5.4% had 
received more than two allografts, and 25.4% were noted to have been treated for more than 
one episode of rejection. Records of the MESOT registry show that 85% of the graft sources 
are from RLD and NRLD [11, 49]. 
Recipients of multiple grafts and those treated for rejection on multiple occasions are 
exposed to higher doses of induction therapy which is associated with PTLD [11]. In contrast 
in this study, all the recipients who developed PTLD were transplanted in the era 1990-1995, 
had not had a previous transplant and received an allograft from a deceased donor and were 
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never treated for rejection. In this study, these possible reasons for increased exposure to 
induction therapy had no significant impact on the risk of developing PTLD. 
Hypertension was the leading cause of renal failure among the black population, and this 
has been seen in numerous studies among this population of patients especially among the 
African population [50]. Among the recipients who were diagnosed with an oncogenic virus, 
8.5% had a PTM, but none of them developed an oncogenic virus-related malignancy. 
4.5 LIMITATIONS 
The main limitation of this study was missing information in the patient records especially the 
mode of dialysis before transplantation and aetiology of the end-stage renal disease. Naicker 
et al reported similar difficulties in reviewing the database of the  South African Dialysis and 
Transplantation Registry (SADTR)  [50]. Some of the information which was absent in the file 
was considered as negative during data collection e.g. oncogenic viruses diagnosed in the 
recipients and number of times recipients were treated for rejection. This introduced 
information bias into the data and hence some causal relationships may not be correct, such 
as the finding that all recipients who developed KS were never diagnosed with HHV8 or all 
patients who had PTLD were never treated for rejections. 
The duration of follow up of some of the recipients was less than 20 years (the total study 
period) and those transplanted after 2005 were followed up for less than 5 years, this could 
have biased the analysis of cancer types, time from transplant to diagnosis and the 
calculation of the incidence of cancer. 
The impact of each immunosuppressive drug on the risk of developing a PTM could not be 
analysed as the numbers of patients exposed to the drugs was small. 
Recipients documented as lost to follow-up are those who did not return for a review, and 
their actual outcome is not known as they might have died or been transferred. 
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Some viruses such as HHV8, HIV, EBV, and HPV are not routinely tested for post-
transplantation at CMJAH and only being tested for when the clinical symptoms suggest its 
necessity. The routine use of this test may be limited by cost. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
46 
 
CHAPTER 5 - CONCLUSIONS AND RECOMMENDATIONS 
Conclusions 
 This study shows that the clinical practice in the renal transplant department in the last 20 
years has not had an impact on the incidence of PTM at CMJAH. 
The recipients transplanted at an older age, those who have been on immunosuppressants 
for a longer duration and those awaiting transplantation beyond two years must be closely 
monitored and surveillance for malignancy undertaken routinely.  
No specific immunosuppressant drug appears to pose a risk for PTM, thus suggesting that 
decreased immunity is the main risk factor for the pathogenesis of malignancy post renal 
transplantation. 
Recommendations 
 The development of an electronic database will improve the quality of record keeping by 
ensuring that all the relevant patient information is kept in one record – dialysis history, 
donor information, clinical notes and results of all investigations done. 
Kaposi sarcoma is a common PTM at CMJAH; routine HHV8 testing must be considered for 
the blacks and any recipients of Mediterranean origin. 
HIV must become a routine test annually post-transplantation as the seroprevalence in the 
country is high, and this will allow for early antiretroviral therapy before the host immunity is 
compromised. 
There is a need for increased awareness and education among the people of South Africa 
on the need to be organ donors as the numbers of transplants are decreasing, but the need 
for transplantation is growing. 
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A prospective multicentre study needs to be done in SA to assess the impact of the newer 
drug classes as more recipients are initiated on these drugs and a cost benefit analysis done 
as the older cheaper drugs may still offer adequate immunosuppression with no increased 
risk of malignancy. 
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Collection Sheet 
DATA COLLECTION SHEET    
 Study No 
Date of data collection 
Demographic Data 
 
Age at time of transplant 
       
Gender (male=1; female=2; missing=3)      
      
Self-identified ethnic group     
(African=1; Indian=2; white=3; Coloured=4; missing=9) 
 
Dialysis Data 
 
Duration on dialysis before transplant (months) 
 
Mode of dialysis (Haemodialysis=1; Peritoneal dialysis=2; both=3) 
 
Immunosuppressant Regimens and Duration of use 
 
Drug Duration in 
Months 
Drug Duration in 
Months 
Prednisone  MMF  
Azathioprine  Tacrolimus  
Cyclosporine  Sirolimus  
Renal Graft 
Source of graft (cadaver=1; Related Living Donor=2; non-related living 
donor=3)  
 
Was an oncogenic virus diagnosed?  (Yes=1; No=2) 
 
Type of virus diagnosed 
(Human Papilloma Virus=1; Epstein-Barr Virus=2;  
Hepatitis B=3; Hepatitis C=4; Human Herpes Virus=5; HIV= 6; CMV=7) 
 
Malignancy Data 
Duration from transplant to diagnosis of cancer (months) 
 
 
Did the recipient develop cancer (Yes=1; No =2) 
Histological Diagnosis 
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